Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Series B | Dead

Total Raised


Last Raised


About ErgoNex Pharma

Provider of products for novel and typically underserved indications. The company focused on the clinical development and commercialization of terguride for the treatment of distinct orphan diseases. It also identifies and develops therapeutic use of existing drugs in new disease areas.

ErgoNex Pharma Headquarter Location

Rütistrasse 20

Appenzell, CH-9050,


41 71 788 40 65

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.